CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

2.46
0  0%
Previous Close 2.46
Open 2.44
Price To Book 0.97
Market Cap 8,199,999
Shares 3,333,333
Volume 1,528
Short Ratio 2.05
Av. Daily Volume 237,145

NewsSee all news

  1. Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

    Cannabinoids bind to A3AR, the target of Can-Fite's drugs Can-Fite's unparalleled expertise in these targets will be utilized to develop new cannabis-based pharmaceuticals The transaction involves technology

  2. Can-Fite to Present at H. C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

    Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and

  3. Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update

     Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up to $10 million plus transfer pricing Preparatory work for an End of Phase II

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
Piclidenoson (CF101)
Glaucoma
Phase 2 data did not meet primary endpoint - March 27, 2019.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 continues to enrol as of August 29, 2019.
Piclidenoson (CF101)
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 trial initiation announced August 2018 continues to enrol as of August 29, 2019.
Piclidenoson (CF101)
Psoriasis
Phase 2 data due 4Q 2019.
Namodenoson (CF102)
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays

    Cannabinoids bind to A3AR, the target of Can-Fite's drugs Can-Fite's unparalleled expertise in these targets will be utilized to develop new cannabis-based pharmaceuticals The transaction involves technology

  2. Can-Fite to Present at H. C. Wainwright 21st Annual Global Investment Conference on September 10, 2019

    Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and

  3. Can-Fite Reports Second Quarter 2019 Financial Results & Provides Clinical Update

     Upfront payments received from licensing deals in South Korea for Piclidenoson and Namodenoson with upfront and milestone payments of up to $10 million plus transfer pricing Preparatory work for an End of Phase II